Shots:

• The expanded approval is based on PREMIER Trial assessing Pipeline Flex in 141 patients with mean aneurysm size of 5.0±1.92 mm
• The study resulted in one-year occlusion rates of 76.7% with use of 1.1 device & 2.2% occurrence of major stroke or neurological death and additional data from PUFs study with efficacy rates 70.8 % @ 1yr. extended to 95% @5yrs.
• Pipeline Flex is a medical device targeted for cardiovascular wide-neck IAs located in the ICA with expanded indication for small or medium IAs and is used to treat patients since 2011 in the US

Ref: Medtronic | Image:  Yahoo Finance